Pilot the pulse: Controlling the multiplicity of receptor dynamics

Trends in Pharmacological Sciences

Volumn 35, Issue 12, 2014, Pages 630-638

  Bock, Andreas ^a   Kostenis, Evi ^b   Tränkle, Christian ^b   Lohse, Martin J ^a,c   Mohr, Klaus ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

biased agonism; dualsteric binding; dynamic ligand binding; G protein coupled receptors; partial agonism; rational ligand design

Indexed keywords

4' AMINOFENOTEROL; ADENOSINE A1 RECEPTOR AGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARIPIPRAZOLE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ARRESTIN; BUPRENORPHINE; CARMOTEROL; CYCLIC AMP; DOBUTAMINE; ERGOTAMINE; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; ISOPRENALINE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MU OPIATE RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; PARATHYROID HORMONE RECEPTOR; PILOCARPINE; SALBUTAMOL; SERINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THYROTROPIN RECEPTOR; TRV 027; TRV 130; UNCLASSIFIED DRUG; UNINDEXED DRUG; VCP 746; LIGAND;

ACUTE HEART FAILURE; ASTHMA; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LIGAND BINDING; MATHEMATICAL ANALYSIS; MOLECULAR DYNAMICS; NONHUMAN; OLIGOMERIZATION; PAIN; POSTOPERATIVE PAIN; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; KINETICS; METABOLISM; MOUSE;

ANIMALS; DRUG DESIGN; HUMANS; KINETICS; LIGANDS; MICE; MODELS, MOLECULAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84913588980     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.10.002     Document Type: Review

References (98)

1. R. Fredriksson The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol. Pharmacol. 63 2003 1256 1272
2. D.E. Gloriam The G protein-coupled receptor subset of the rat genome BMC Genomics 8 2007 338
3. M. Rask-Andersen Trends in the exploitation of novel drug targets Nat. Rev. Drug Discov. 10 2011 579 590
4. V. Katritch Structure-function of the G protein-coupled receptor superfamily Annu. Rev. Pharmacol. Toxicol. 53 2013 531 556
5. A.J. Venkatakrishnan Molecular signatures of G-protein-coupled receptors Nature 494 2013 185 194
6. A. Christopoulos Advances in GPCR allostery: from function to structure Mol. Pharmacol. 86 2014 463 478
7. D. Wootten Emerging paradigms in GPCR allostery: implications for drug discovery Nat. Rev. Drug Discov. 12 2013 630 644
8. 2 muscarinic acetylcholine receptor Drug Discov. Today Technol. 10 2013 245 252
9. J.R. Lane Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 34 2013 59 66
10. C. Valant The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 52 2012 153 178
11. M. Simon Diversity of G proteins in signal transduction Science 252 1991 802 808
12. R.J. Lefkowitz, and S.K. Shenoy Transduction of receptor signals by beta-arrestins Science 308 2005 512 517
13. K. Xiao Functional specialization of beta-arrestin interactions revealed by proteomic analysis Proc. Natl. Acad. Sci. U.S.A. 104 2007 12011 12016
14. S.L. Ritter, and R.A. Hall Fine-tuning of GPCR activity by receptor-interacting proteins Nat. Rev. Mol. Cell Biol. 10 2009 819 830
15. + exchange Nature 392 1998 626 630
16. M.J. Marinissen, and J.S. Gutkind G-protein-coupled receptors and signaling networks: emerging paradigms Trends Pharmacol. Sci. 22 2001 368 376
17. D. Calebiro Signaling by internalized G-protein-coupled receptors Trends Pharmacol. Sci. 31 2010 221 228
18. T. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62 2010 265 304
19. 2-adrenergic receptor activation Cell 152 2013 532 542
20. J-P. Changeux, and S. Edelstein Conformational selection or induced-fit? 50 years of debate resolved F1000 Biol. Rep. 3 2011 19
21. P. Bremner Partial vs full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol Chest 109 1996 957 962
22. W.W. Zuurmond Partial versus full agonists for opioid-mediated analgesia-focus on fentanyl and buprenorphine Acta Anaesthesiol. Belg. 53 2002 193 201
23. J. Sorge, and R. Sittl Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study Clin. Ther. 26 2004 1808 1820
24. R.B. Mailman, and V. Murthy Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr. Pharm. Des. 16 2010 488 501
25. 2-Adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists J. Biol. Chem. 272 1997 23871 23879
26. 2-adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists J. Biol. Chem. 280 2005 22165 22171
27. 2-adrenoceptor Nat. Chem. Biol. 2 2006 417 422
28. 1-adrenergic receptor Nature 469 2011 241 244
29. + currents J. Physiol. 592 2014 1237 1248
30. K.M. Page The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis Eur. J. Pharmacol. 289 1995 429 437
31. B.T. Zhu Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: a theory J. Theor. Biol. 181 1996 273 291
32. A. Bock Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor Nat. Chem. Biol. 10 2014 18 20
33. G. Pochetti Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor γ ligand-binding domain in the complex with two enantiomeric ligands J. Biol. Chem. 282 2007 17314 17324
34. J.B. Bruning Coupling of receptor conformation and ligand orientation determine graded activity Nat. Chem. Biol. 6 2010 837 843
35. S. Srinivasan Ligand-binding dynamics rewire cellular signaling via estrogen receptor-α Nat. Chem. Biol. 9 2013 326 332
36. J.C. Nwachukwu Resveratrol modulates the inflammatory response via an estrogen receptor-signal integration network Elife 3 2014 e02057
37. Y. Anami A mixed population of antagonist and agonist binding conformers in a single crystal explains partial agonism against vitamin D receptor: active vitamin D analogues with 22 R-alkyl group J. Med. Chem. 10 2014 4351 4367
38. T. Kenakin Agonist-receptor efficacy. II. Agonist trafficking of receptor signals Trends Pharmacol. Sci. 16 1995 232 238
39. J.W. Wisler Recent developments in biased agonism Curr. Opin. Cell Biol. 27 2014 18 24
40. R. Seifert Functional selectivity of G-protein-coupled receptors: from recombinant systems to native human cells Biochem. Pharmacol. 86 2013 853 861
41. J. Shonberg Biased agonism at G protein-coupled receptors: the promise and the challenges-a medicinal chemistry perspective Med. Res. Rev. 2014 10.1002/med.21318
42. L.M. Luttrell Minireview: more than just a hammer: ligand 'bias' and pharmaceutical discovery Mol. Endocrinol. 28 2014 281 294
43. T. Kenakin What is pharmacological 'affinity'? Relevance to biased agonism and antagonism Trends Pharmacol. Sci. 35 2014 434 441
44. L. Zhou, and L.M. Bohn Functional selectivity of GPCR signaling in animals Curr. Opin. Cell Biol. 27 2014 102 108
45. 1 receptor entity Nat. Chem. Biol. 8 2012 622 630
46. J.D. Violin, and R.J. Lefkowitz β-Arrestin-biased ligands at seven-transmembrane receptors Trends Pharmacol. Sci. 28 2007 416 422
47. C. Valant A novel mechanism of G protein-coupled receptor functional selectivity: muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand J. Biol. Chem. 283 2008 29312 29321
48. A. Bock The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling Nat. Commun. 3 2012 1044
49. 15 J. Pharmacol. Exp. Ther. 321 2007 1193 1207
50. S. Blättermann A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer Nat. Chem. Biol. 8 2012 631 638
51. J.D. Violin Biased ligands at G-protein-coupled receptors: promise and progress Trends Pharmacol. Sci. 35 2014 308 316
52. D.G. Soergel First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers J. Clin. Pharmacol. 53 2013 892 899
53. D.G. Soergel Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers Pain 155 2014 1829 1835
54. R. Rahmeh Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy Proc. Natl. Acad. Sci. U.S.A. 109 2012 6733 6738
55. 19F-NMR Science 335 2012 1106 1110
56. C. Wang Structural basis for molecular recognition at serotonin receptors Science 340 2013 610 614
57. D. Wacker Structural features for functional selectivity at serotonin receptors Science 340 2013 615 619
58. T. Disingrini Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors J. Med. Chem. 49 2006 366 372
59. J. Antony Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J. 23 2008 442 450
60. 2 ACh receptor Br. J. Pharmacol. 169 2013 357 370
61. 2 muscarinic acetylcholine receptor bound to an antagonist Nature 482 2012 547 551
62. R.O. Dror Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs Nature 503 2013 295 299
63. A.C. Kruse Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 504 2013 101 106
64. 2-adrenoceptor J. Biol. Chem. 289 2014 19351 19363
65. 2 receptor J. Med. Chem. 56 2013 9199 9221
66. 3 receptor partial agonists J. Med. Chem. 57 2014 4861 4875
67. 2 receptor J. Med. Chem. 57 2014 4924 4939
68. W. Liu Serial femtosecond crystallography of G protein-coupled receptors Science 342 2013 1521 1524
69. C. Valant Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist Proc. Natl. Acad. Sci. U.S.A. 111 2014 4614 4619
70. 1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment MAbs 6 2014 246 261
71. 1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy Am. Heart J. 152 2006 697 704
72. T. Kenakin, and A. Christopoulos Signalling bias in new drug discovery: detection, quantification and therapeutic impact Nat. Rev. Drug Discov. 12 2013 205 216
73. S. Ferré G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives Pharmacol. Rev. 66 2014 413 434
74. B. Duthey A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor J. Biol. Chem. 277 2002 3236 3241
75. V. Hlavackova Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR EMBO J. 24 2005 499 509
76. M. Damian Asymmetric conformational changes in a GPCR dimer controlled by G-proteins EMBO J. 25 2006 5693 5702
77. 2A-adrenergic and μ-opioid receptors controls cell signaling Nat. Chem. Biol. 4 2008 126 131
78. S. Armando The chemokine CXC4 and CC2 receptors form homo- and heterooligomers that can engage their signaling G-protein effectors and β-arrestin FASEB J. 28 2014 4509 4523
79. K.G. Harikumar Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery Proc. Natl. Acad. Sci. U.S.A. 109 2012 18607 18612
80. M. Bouvier Oligomerization of G-protein-coupled transmitter receptors Nat. Rev. Neurosci. 2 2001 274 286
81. 1 dopamine receptor function without affecting receptor oligomerization J. Biol. Chem. 273 1998 30244 30248
82. L. Covic Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides Proc. Natl. Acad. Sci. U.S.A. 99 2002 643 648
83. K. O'Callaghan Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development J. Biol. Chem. 287 2012 12787 12796
84. J. Quoyer Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein Proc. Natl. Acad. Sci. U.S.A. 110 2013 5088 5097
85. 2-adrenergic receptor function by conformationally selective single-domain intrabodies Mol. Pharmacol. 85 2014 472 481
86. D. Calebiro Persistent cAMP-signals triggered by internalized G-protein-coupled receptors PLoS Biol. 7 2009 e1000172
87. S. Ferrandon Sustained cyclic AMP production by parathyroid hormone receptor endocytosis Nat. Chem. Biol. 5 2009 734 742
88. F. Mullershausen Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors Nat. Chem. Biol. 5 2009 428 434
89. R. Irannejad Conformational biosensors reveal GPCR signalling from endosomes Nature 495 2013 534 538
90. M.J. Lohse, and D. Calebiro Cell biology: receptor signals come in waves Nature 495 2013 457 458
91. 1 signaling J. Exp. Med. 211 2014 685 700
92. T.N. Feinstein Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin J. Biol. Chem. 288 2013 27849 27860
93. B. Chini, and M. Parenti G-protein-coupled receptors, cholesterol and palmitoylation: facts about fats J. Mol. Endocrinol. 42 2009 371 379
94. K. Björk, and P. Svenningsson Modulation of monoamine receptors by adaptor proteins and lipid rafts: role in some effects of centrally acting drugs and therapeutic agents Annu. Rev. Pharmacol. Toxicol. 51 2011 211 242
95. E.V. Gurevich G protein-coupled receptor kinases: more than just kinases and not only for GPCRs Pharmacol. Ther. 133 2012 40 69
96. 2-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin Sci. Signal. 4 2011 ra51
97. J.M. Janz Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4 J. Am. Chem. Soc. 133 2011 15878 15881
98. L.T. May Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 47 2007 1 51